A quantitative investigation of fucosylated serum glycoproteins with application to esophageal adenocarcinoma

Abstract

Whereas glycoproteomic studies provide unique opportunities for cancer research, it has been necessary to develop specific methods for analysis of oncologically interesting glycoproteins. We describe a general, multimethodological approach for quantitative glycoproteomic analysis of fucosylated glycoproteins in human blood serum. A total of 136 putative fucosylated glycoproteins were identified with very high confidence in three clinically relevant sample pools (N=5 for each), with a mean coefficient of variation of 3.1% observed for replicate analyses. Two samples were collected from subjects diagnosed with esophagus disease states, high-grade dysplasia (HGD) plus esophageal adenocarcinoma (EAC), while the third sample was representative of a disease-free (DF) condition. Some glycoproteins, observed to be significantly upregulated in EAC, i.e. more than 2-fold higher than in the DF condition, are briefly discussed. Further investigation will be necessary to validate these findings; however, the method itself is demonstrated to be an effective tool for quantitative glycoproteomics of clinical samples.

Transcriptome profiling in oral cavity and esophagus tissues from (S)‐N′‐nitrosonornicotine‐treated rats reveals candidate genes involved in human oral cavity and esophageal carcinogenesis

“…In addition to copy number amplification, both ATP13A5 and LY6E showed mRNA upregulation in human ESCA, suggesting their potential roles in early onset and maintenance of tumorigenesis as a result of increases in genetic activities. The role of ATP13A5, a member of P5-ATPases which are involved in the transport of inorganic cations and other substrates across cell membranes [45], in cancer is unknown, whereas FETUB, a member of the cystatin protein family, is overexpressed in human high grade esophageal dysplastic lesions and adenocarcinoma [46]. LY6E is a negative immune regulator of monocytes, known to be overexpressed in several cancers, including ovarian, pancreatic, lung, gastric, and various breast cancers [47].…”